Prostanoids receptors signaling in different diseases/cancers progression

Journal of Receptors and Signal Transduction

Volumn 33, Issue 1, 2013, Pages 14-27

  Yang, Yang ^a   Tang, Li Qin ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer progression; Disease; Prostanoid receptors; Signaling

Indexed keywords

3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; ACETYLSALICYLIC ACID; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; INDOLEACETIC ACID DERIVATIVE; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OC 000459; PHENYLACETIC ACID DERIVATIVE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROSTANOID RECEPTOR; QUINOLINE DERIVATIVE; RAMATROBAN; RAMATROBAN DERIVATE; S 5751; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC RHINITIS; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BIRTH; BLADDER CANCER; BLOOD PRESSURE; BRAIN CANCER; BREAST CANCER; BRONCHUS HYPERREACTIVITY; CANCER GROWTH; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PERIODONTITIS; COLON CANCER; COLORECTAL CANCER; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENDOMETRIUM CARCINOMA; EOSINOPHILIC PUSTULAR FOLLICULITIS; FLUSHING; FOLLICULITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GLAUCOMA; HOMEOSTASIS; HUMAN; ICOSANOID METABOLISM; LABOR; LUNG CANCER; LUNG FIBROSIS; NONHUMAN; OTITIS MEDIA; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; PROTEIN DOMAIN; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION;

EID: 84873127246     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2012.752003     Document Type: Review

References (135)

1. Shindou H, Hishikawa D, Harayama T, et al. Recent progress on acyl CoA: lysophospholipid acyltransferase research. J Lipid Res 2009;50:S46-51.
2. Capra V, Back M, Barbieri SS, et al. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 2012:1-75pp [Epub ahead of print].
3. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-193.
4. Menter DG, DuBois RN. Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol 2012;2012:723419.
5. Takeuchi K, Kato S, Amagase K. Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity. J Pharmacol Sci 2010;3:248-61.
6. Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends. Immunol 2002;23:144-50. (Pubitemid 34178297)
7. Shiraishi Y, Asano K, Nakajima T, et al. Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther 2005;312:954-60. (Pubitemid 40293753)
8. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6:313-25. (Pubitemid 46505882)
9. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-61. (Pubitemid 32524457)
10. Gosset P, Bureau F, Angeli V, et al. Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of nai?ve Th cells. J Immunol 2003; 170:4943-52. (Pubitemid 36554723)
11. Nantel F, Fong C, Lamontagne S, et al. Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa. Prostaglandins Other Lipid Mediat 2004; 73:87-101. (Pubitemid 38450719)
12. Wright DH, Ford-Hutchinson AW, Chadee K, et al. The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. Br J Pharmacol 2000;31:1537-45. (Pubitemid 32056417)
13. Moreland RB, Nehra A, Kim NN, et al. Expression of functional prostaglandin D(DP) receptors in human corpus cavernosum smooth muscle. Int J Impot Res 2002;14:446-52. (Pubitemid 36068419)
14. Chen Y, Perussia B, Campbell KS. Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J Immunol 2007;179:2766-73.
15. Mohri I, Taniike M, Taniguchi H, et al. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J Neurosci 2006;26:4383-93. (Pubitemid 44315397)
16. Bousquet J. Allergic rhinitis and its impact on asthma (ARIA). Clin Exp Allergy Rev 2003;3:43-5. (Pubitemid 36241364)
17. Johnson JR, Wiley RE, Fattouh R, et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care Med 2004;169: 378-85. (Pubitemid 38134818)
18. Arima M, Fukuda T. Prostaglandin D2 and TH2 inflammation in the pathogenesis of bronchial asthma. Korean J Intern Med 2011; 26:8-18.
19. Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program. Am J Respir Crit Care Med 2011; 183:299-309.
20. Kabashima K, Narumiya S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003; 69:187-94. (Pubitemid 36976174)
21. Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000;287:2013-17.
22. Matsuoka T, Narumiya S. Prostaglandin receptor signaling in disease. Sci World J 2007;7:1329-47. (Pubitemid 47435437)
23. Giles H, Leff P, Bolofo ML, et al. The classification of prostaglandin DP receptors in platelets and vasculature using BWA868C, a novel, selective and potent competitive antagonist. Br J Pharmacol 1989;96:291-300. (Pubitemid 19045102)
24. Arimura A, Yasui K, Kishino J, et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 2001;29:411-19. (Pubitemid 32673391)
25. Hirano Y, Shichijo M, Ikeda M, et al. Prostanoid DP receptor antagonists suppress symptomatic asthma-like manifestation by distinct actions from a glucocorticoid in rats. Eur J Pharmacol 2011;666:233-41.
26. Norman P. DP2 receptor antagonists in development. Expert Opin Invest Drugs 2010;19:947-61.
27. Hirai H, Tanaka K, Takano S, et al. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 2002;168:981-5. (Pubitemid 34094458)
28. Bo?hm E, Sturm GJ, Weiglhofer I, et al. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem 2004;279:7663-70. (Pubitemid 38294647)
29. Sandham DA, Adcock C, Bala K, et al. 7-Azaindole-3-acetic acid derivatives: potent and selective CRTH2 receptor antagonists. Bioorg Med Chem Lett 2009;19:4794-8.
30. Sandham DA, Aldcroft C, Baettig U, et al. 2-Cycloalkyl phenoxyacetic acid CRTH2 receptor antagonists. Bioorg Med Chem Lett 2007;17:4347-50. (Pubitemid 47021382)
31. Liu J, Wang Y, Sun Y, et al. Tetrahydroquinoline derivatives as CRTH2 antagonists. Bioorg Med Chem Lett 2009;19:6840-4.
32. Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009;158:104-45.
33. Schuligoi R, Sturm E, Luschnig P, et al. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 2010;85:372-82.
34. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8-16.
35. Okuda, M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann. Allergy Asthma Immunol 2003;91:288-96. (Pubitemid 37174163)
36. Stebbins KJ, Broadhead AR, Correa LD, et al. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010;638:142-9.
37. Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812-17. (Pubitemid 34634400)
38. Nomiya R, Okano M, Fujiwara T, et al. CRTH2 plays an essential role in the pathophysiology of Cry j 1-induced pollinosis in mice. J Immunol 2008;180:5680-8.
39. Xavier RJ, Podolsky D K. Unravelling the pathogenesis of in flammatory bowel disease. Nature 2007;448:427-34. (Pubitemid 47123518)
40. Zamuner SR, Bak AW, Devchand PR, et al. Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase- 2-derived prostaglandin d2. Am J Pathol 2005; 167:1293-300. (Pubitemid 41541415)
41. Kim N, Luster AD. Regulation of immune cells by eicosanoid receptors. Scientific World J 2007;7:1307-28. (Pubitemid 47435438)
42. Zamuner SR, Warrier N, Buret AG, et al. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 2003;52:1714-20. (Pubitemid 37521248)
43. Kariya S, Okano M, Aoji K, et al. Role of macrophage migration inhibitory factor in otitis media with effusion in adults. Clin Diagn Lab Immunol 2003;10:417-22. (Pubitemid 36592969)
44. Smirnova MG, Kiselev SL, Gnuchev NV, et al. Role of the proinflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6 and interleukin-8 in the pathogenesis of the otitis media with effusion. Eur Cytokine Network 2002; 13:161-72. (Pubitemid 34747917)
45. Harada T, Juhn SK, Kim Y, et al. Arachidonic acid metabolism by isolated and cultured middle ear epithelial cells from the chinchilla. Eur Arch Otorhinolaryngol 1993;250:220-3. (Pubitemid 23235993)
46. Eguchi M, Kariya S, Okano M, et al. Lipopolysaccharide induces proinflammatory cytokines and chemokines in experimental otitis media through the prostaglandin D2 receptor (DP)-dependent pathway. Clin Exper Immunol 2010;163:260-9.
47. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:13180-5. (Pubitemid 44338936)
48. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. (Pubitemid 351160157)
49. Brule S, Wallemme L, Uwambayinema F, et al. The D prostanoid receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]- 2,5-dioxo)-4-imidazolidineheptanoic acid] inhibits fibroblast proliferation and bleomycin-induced lung fibrosis in mice. J Pharmacol Exper Therap 2010;335:472-9.
50. Shimura C, Satoh T, Igawa K, et al. Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin. Am J Pathol 2011;176:227-37.
51. Monneret G, Gravel S, Diamond M, et al. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001;98:1942-8.
52. Nakahigashi K, Hiromi D, Otsuka A, et al. PGD2 induces eotaxin-3 via PPARg from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol 2012;129:536-43.
53. Lubberts E, Joosten LA, van den Bersselaar L, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999;163:4546-56. (Pubitemid 29474525)
54. Maicas N, Ibanez L, Alcaraz MJ, et al. Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis. Amer College Rheumatol 2012;64:130-40.
55. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258:1798-801. (Pubitemid 23087348)
56. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114. (Pubitemid 41025967)
57. Papaliodis D, Boucher W, Kempuraj D, et al. Niacin-induced ''flush'' involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther 2008;327:665-72.
58. Trivedi SG, Newson J, Rajakariar R, et al. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. PNAS 2006;103:5179-84.
59. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Prac 2009;63:1369-77.
60. Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009;20:467-76
61. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009;5:901-8.
62. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007;59:207-24. (Pubitemid 47481434)
63. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-7. (Pubitemid 47100657)
64. Dey I, Lejeune M, Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 2006;149:611-23. (Pubitemid 44748054)
65. Rodriguez-Lagunas MJ, Martin-Venegas R, Moreno JJ, et al. PGE2 promotes Ca2+-mediated epithelial barrier disruption through EP1 and EP4 receptors in Caco-2 cell monolayers. Am J Physiol Cell Physiol 2010;299:C324-34.
66. Francesco P, Schena LG. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16:S30-3.
67. Hirasawa Y, Sakai T, Ito M, et al. Advanced-glycation-end- productcholesterol- aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway. Eur J Pharmacol 2011;672:159-68.
68. Urdyke P, Rendshorstwj A. EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 2000;279:F755-64.
69. Makino H, Tanaka I, Mukoyama M, et al. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 2002;13:1757-65. (Pubitemid 34700600)
70. Suganami T, Tanaka I, Mukoyama M, et al. Altered growth response to prostaglandin E2 and its receptor signaling in mesangial cells from stroke-prone spontaneously hypertensive rats. J Hypertens 2001;19:1095-103. (Pubitemid 32493644)
71. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518-27.
72. Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007;59: 247-58. (Pubitemid 47299726)
73. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004;31:64-73. (Pubitemid 38543941)
74. Wang D, Buchanan FG, Wang H, et al. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogenactivated protein kinase cascade. Cancer Res 2005;65:1822-9. (Pubitemid 40478610)
75. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
76. Kim S-H, Park Y-Y, Kim S-W, et al. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res 2011;71:7010-20.
77. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005;115:118-28. (Pubitemid 40693079)
78. De Mattei M, Varani K, Masieri FF, et al. Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts. Osteoarthr Cartilage 2009;17:252-62.
79. Kunisch E, Jansen A, Kojima F, et al. Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-a on synovial fibroblasts via specific E prostanoid receptors/ cAMP. J Immunol 2009;183:1328-36.
80. Akangi J, Nozaki T, Satoh M, et al. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006;6:383-94. (Pubitemid 44941926)
81. Nozaki TS, Ito H, Mitomi H, et al. Endogenous prostaglandin E2 inhibits aberrant overgrowth of rheumatoid synovial tissue and the development of osteoclast activity through EP4 receptor. Arthr Rheumat 2011;63:2595-605.
82. Miyaura C, Inada M, Suzawa T, et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000;275:19819-23. (Pubitemid 30441583)
83. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55. (Pubitemid 47403272)
84. Pavord ID, Wong CS, Williams J, et al. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 1993;148:87-90. (Pubitemid 23187223)
85. Fortner CN, Breyer RM, Paul RJ. EP2 receptors mediate airway relaxation to substance P, ATP, and PGE2. Am J Physiol Lung Cell Mol Physiol 2001;281:L469-74.
86. Buckley J, Birrell MA, Maher SA, et al. EP4 receptor as a new target for bronchodilator therapy. Thorax 2011;66:1029-35.
87. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression with the deletion of reference 87 please adjust the numbers of the intext citations accordingly in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxiainducible factor 1. Cancer Res 2003;63:2330-4. (Pubitemid 36538645)
88. Spinella F, Rosano L, Di Castro V, et al. Endothelin 1-induced prostaglandinE2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 2004;279:46700-5. (Pubitemid 39523128)
89. Amano H, Hayashi J, Endo H, et al. Host prostaglandin E2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197:221-32. (Pubitemid 36152316)
90. Alfranca A, Lopez-Oliva JM, Genis L, et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/ Alk5 signaling pathway. Blood 2008;112:1120-8.
91. Zhang Y, Daaka Y. PGE2 promotes angiogenesis through EP4 and PKA Cg pathway. Blood 2011;118:5355-64.
92. Eley BM, Cox SW. Proteolytic and hydrolytic enzymes from putative periodontal pathogens: characterization, molecular genetics, effects on host defenses and tissues and detection in gingival crevice fluid. Periodontol 2003;31:105-24. (Pubitemid 37487412)
93. Noguchi K, Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease. Periodontol 2007; 43:85-101.
94. Oka H, Miyauchi M, Sakamoto K, et al. PGE2 activates cementoclastogenesis by cementoblasts via EP4. J Dent Res 2007;86:974-9.
95. Guan SM, Shu L, Fu SM, et al. Prevotella intermedia upregulates MMP-1 and MMP-8 expression in human periodontal ligament cells. FEMS Microbiol Lett 2009;299:214-22.
96. Cirillo R, Tos EG, Page P, et al. Arrest of preterm labor in rat and mouse by an oral and selective nonprostanoid antagonist of the prostaglandin F2a receptor(FP). Am J Obstet Gynecol 2007;197:e1-9.
97. Sales KJ, Boddy SC, Williams AR, et al. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 2007; 148:3635-44. (Pubitemid 47105849)
98. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-newlight through old windows. J Steroid Biochem Mol Biol 2008;108:221-9. (Pubitemid 351179637)
99. Jabbour HN, Sales KJ, Boddy SC, et al. A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2asynthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology 2005;146:4657-64. (Pubitemid 41446603)
100. Sales KJ, Boddy SC, Jabbour HN. F-Prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene 2008;27:2466-77. (Pubitemid 351521090)
101. Sales KJ, Grant V, Cook IH, et al. Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2a-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol 2010;176:435-5.
102. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53:S107-20.
103. Hutchinson AJ, Coons SC, Chou C-L, et al. Induction of angiogenic immediate early genes by activation of FP prostanoid receptors in cultured human ciliary smooth muscle cells. Curr Eye Res 2010;35:408-18.
104. Swales J. Textbook of hypertension. Boston: Blackwell Scientific; 1994.
105. Yu Y, Lucitt MB, Stubbe J, et al. Prostaglandin F2a elevates blood pressure and promotes atherosclerosis. PNAS 2009; 106:7985-90.
106. Nussberger J, Aubert JF, Bouzourene K, et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008;51: 1306-11. (Pubitemid 351555942)
107. Slater DM, Zervou S, Thornton S. Prostaglandins and prostanoid receptors in human pregnancy and parturition. J Soc Gynecol Invest 2002;9:118-24. (Pubitemid 34497139)
108. Hirst JJ, Parkington HC, Young IR, et al. Delay of preterm birth in sheep by THG113.31, a prostaglandin F2a receptor antagonist. Am J Obstet Gynecol 2005;193:256-66. (Pubitemid 40991854)
109. Bogatcheva NV, Sergeeva MG, Dudek SM, et al. Arachidonic acid cascade in endothelial pathobiology. Microvasc Res 2005;69:107-27. (Pubitemid 40731489)
110. Kuo C-H, Lin C-H, Yang S-N, et al. Effect of PGI2 analogs on cytokine expression in human myeloid dendritic cells via epigenetic regulation. Mol Med 2012;18:433-44.
111. Idzko M, Hammad H, van Nimwegen M, et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 2007;117:464-72. (Pubitemid 46203975)
112. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007;28:551-8. (Pubitemid 350101420)
113. Hatae T, Wada M, Yokoyama C, et al. Prostacyclin-dependent apoptosis mediated by PPARd. J Biol Chem 2001;276:46260-7.
114. Dunn MJ. Prostaglandin I2 and the kidney. Arch Mal Coeur 1989;82:27-31.
115. Dwyer-Nield LD, Srebernak MC, Barrett BS, et al. Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis 2005;26:1196-206. (Pubitemid 41417896)
116. Iniguez MA, Cacheiro-Llaguno C, Cuesta N, et al. Prostanoid function and cardiovascular disease. Arch Physiol Biochem 2008;114:201-9. (Pubitemid 352009306)
117. Boswell MG, Zhou W, Newcomb DC, et al. PGI2 as a regulator of CD4+ subset differentiation and function. Prostaglandins Other Lipid Mediat 2011;96:21-6.
118. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S-61S. (Pubitemid 38759718)
119. Nakahata, N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Therap 2008;118:18-35.
120. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005;48:1439-44. (Pubitemid 41175492)
121. Wright WS, Messina JE, Harris NR. Attenuation of diabetesinduced retinal vasoconstriction by a thromboxane receptor antagonist. Exper Eye Res 2009;88:106-112. United States Cancer Statistics: 1999-2007.
122. Incidence and mortality web-based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. U.S.C.S.W. Group; 2010.
123. Nie D, Che M, Zacharek A, et al. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Amer J Pathol 2004;164:429-39. (Pubitemid 38364659)
124. Watkins, G, Douglas-Jones A, Mansel RE, et al. Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. Int Sem Surg Oncol 2005;2:23.
125. Wei J, Yan W, Li X, et al. Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer 2010;69:26-32.
126. Cathcart MC, Gately K, Cummins R, et al. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol Cancer 2011;10:25.
127. McAfee AJ, McSorley EM, Cuskelly GJ, et al. Red meat consumption: an overview of the risks and benefits. Meat Sci 2010;84:1-13.
128. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Therapy 2006; 6:1087-104. (Pubitemid 44203386)
129. Giese A, Hagel C, Kim EL, et al. Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-Oncol 1999;1:3-13.
130. Moussa O, Riker JM, Klein J, et al. Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 2008;27:55-62.
131. Moussa O, Ashton AW, Fraig M, et al. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res 2008;68:4097-104.
132. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004;117:3-32.
133. Miyamoto M, Ohno M, Yamada N, et al. TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood. Thromb Haemost 2010;104:788-95.
134. Pal S, Wu J, Murray JK, et al. An antiangiogenic neurokinin- B/thromboxane A2 regulatory axis. J Cell Biol 2006;174: 1047-58. (Pubitemid 44455192)
135. Yoshimoto A, Kasahara K, Kawashima A, et al. Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol Rep 2005;13:1049-57.